Multiple myeloma (MM) is a highly heterogeneous disease characterised by neoplastic clonal plasma cell proliferation and a wide range of clinical manifestations including skeletal destruction, hypercalcemia, anaemia, renal failure, and immune suppression. Currently accepted and widely used staging criteria for MM patients are the International staging system (ISS) and the Revised International staging system (R-ISS). In order to anticipate outcomes for these patients and to select a risk-adapted therapy, a staging approach that can classify MM patients based on risk at the time of diagnosis itself may be helpful. For MM patients with high-risk characteristics, recognising their risk profile at diagnosis and maintaining remission are clinically significant. In this study, we looked at the risk stratification done in our hospital setting among Newly diagnosed multiple myeloma patients (NDMM), and we noticed a time-based improvement in both ISS and R-ISS documentation, which reflects the evolution of better risk stratification of patients in clinical practice.